Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Relatlimab by Bristol-Myers Squibb for Metastatic Colorectal Cancer: Likelihood of Approval
Relatlimab is under clinical development by Bristol-Myers Squibb and currently in Phase II for Metastatic Colorectal Cancer. According to GlobalData,...
Relatlimab by Bristol-Myers Squibb for Metastatic Uveal Melanoma: Likelihood of Approval
Relatlimab is under clinical development by Bristol-Myers Squibb and currently in Phase II for Metastatic Uveal Melanoma. According to GlobalData,...
Relatlimab by Bristol-Myers Squibb for Melanoma: Likelihood of Approval
Relatlimab is under clinical development by Bristol-Myers Squibb and currently in Phase II for Melanoma. According to GlobalData, Phase II...
Relatlimab by Bristol-Myers Squibb for Recurrent Glioblastoma Multiforme (GBM): Likelihood of Approval
Relatlimab is under clinical development by Bristol-Myers Squibb and currently in Phase I for Recurrent Glioblastoma Multiforme (GBM). According to...
Relatlimab by Bristol-Myers Squibb for Non-Small Cell Lung Cancer: Likelihood of Approval
Relatlimab is under clinical development by Bristol-Myers Squibb and currently in Phase II for Non-Small Cell Lung Cancer. According to...
Relatlimab by Bristol-Myers Squibb for Metastatic Hepatocellular Carcinoma (HCC): Likelihood of Approval
Relatlimab is under clinical development by Bristol-Myers Squibb and currently in Phase II for Metastatic Hepatocellular Carcinoma (HCC). According to...
Relatlimab by Bristol-Myers Squibb for Solid Tumor: Likelihood of Approval
Relatlimab is under clinical development by Bristol-Myers Squibb and currently in Phase II for Solid Tumor. According to GlobalData, Phase...
Relatlimab by Bristol-Myers Squibb for Metastatic Melanoma: Likelihood of Approval
Relatlimab is under clinical development by Bristol-Myers Squibb and currently in Phase II for Metastatic Melanoma. According to GlobalData, Phase...
Relatlimab by Bristol-Myers Squibb for Melanoma: Likelihood of Approval
Relatlimab is under clinical development by Bristol-Myers Squibb and currently in Phase II for Melanoma. According to GlobalData, Phase II...
Relatlimab by Bristol-Myers Squibb for Recurrent Glioblastoma Multiforme (GBM): Likelihood of Approval
Relatlimab is under clinical development by Bristol-Myers Squibb and currently in Phase I for Recurrent Glioblastoma Multiforme (GBM). According to...